Key result
Higher circulating B-type natriuretic peptide levels were independently associated with an increased risk of osteoporosis in patients with type 2 diabetes (OR 2.710).
Why the study?
Altered BNP levels have been linked to lower bone mineral density and osteoporosis in other populations, but the relationship in patients with type 2 diabetes mellitus has not been studied.
Is circulating BNP associated with osteoporosis in patients with type 2 diabetes mellitus?
Cross-Sectional (n=314)
No
Is circulating BNP associated with osteoporosis in patients with type 2 diabetes mellitus?
Higher circulating BNP levels are independently associated with the presence of osteoporosis in patients with type 2 diabetes mellitus, suggesting its potential utility as a biomarker.
Answers are grounded in this paper and cite their sources.
Caution against BNP-guided osteoporosis screening in type 2 diabetes; hypothesis-generating and requires prospective validation.
BACKGROUND: Altered circulating levels and genetic variation of B-type natriuretic peptide (BNP), has been associated with lower bone mineral density (BMD) values and incidence of osteoporosis in peritoneal dialysis patients, renal transplant recipients, and postmenopausal women. The potential relationship of circulating BNP with osteoporosis in patients with type 2 diabetes mellitus (T2DM), however, has not yet been studied. METHODS: Circulating BNP levels were measured in 314 patients with T2DM, and participants were divided into normal BMD group (n = 73), osteopenia group (n = 120), and osteoporosis group (n = 121). The association of circulating BNP with diabetic osteoporosis and other parameters was analyzed. RESULTS: Circulating BNP was significantly higher in diabetic osteoporosis subjects than normal and osteopenia groups (P < 0.01 or P < 0.05). Circulating BNP levels correlated significantly and positively with neutrophil to lymphocyte ratio, systolic blood pressure, urinary albumin-to-creatinine ratio, and prevalence of hypertension, peripheral arterial disease, diabetic retinopathy, peripheral neuropathy, and nephropathy, and negatively with triglyceride, fasting blood glucose, lymphocyte count, hemoglobin, estimated glomerular filtration rate, bilirubin, osteoporosis self-assessment tool for Asians, BMD at different skeletal sites and corresponding T scores (P < 0.01 or P < 0.05). After multivariate adjustment, circulating BNP remained independently significantly associated with the presence of osteoporosis (odds ratio, 2.710; 95% confidence interval, 1.690-4.344; P < 0.01). BMD at the femoral neck and total hip and corresponding T scores were progressively decreased, whereas the prevalence of osteoporosis was progressively increased with increasing BNP quartiles (P for trend< 0.01). Moreover, receiver-operating characteristic analysis revealed that the optimal cutoff point of circulating BNP to indicate diabetic osteoporosis was 16.35 pg/ml. CONCLUSIONS: Circulating BNP level may be associated with the development of osteoporosis, and may be a potential biomarker for diabetic osteoporosis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) conducted a cross-sectional in Type 2 diabetes mellitus and osteoporosis (n=314). Circulating B-type natriuretic peptide (BNP) vs. Lower circulating BNP levels was evaluated on Presence of osteoporosis (OR 2.710, 95% CI 1.690-4.344, p=<0.01). Higher circulating B-type natriuretic peptide levels were independently associated with an increased risk of osteoporosis in patients with type 2 diabetes (OR 2.710).
Synapse has enriched 10 related papers. Consider them for comparative context: